At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 303 enrolled
Drug / intervention
GVAX Pancreas Vaccine +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating GVAX Pancreas Vaccine, CRS-207, and 2 other interventions for 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer. Completed, enrolled 303 participants across 21 sites in 2 countries.
Detailed Summary
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
CollaboratorsJohns Hopkins University
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartFeb 2014
Primary CompletionJan 2016
Study CompletionAug 2016
TodayJul 2026
First PostedDec 9, 2013
Enrollment StartFeb 5, 2014
Primary CompletionJan 1, 2016
Study CompletionAug 23, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.6 years ago
Interventions
GVAX Pancreas Vaccinebiological
CRS-207biological
Chemotherapydrug
Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
cyclophosphamidedrug